## ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 27. ja	januar 2021	
Your name:	Tom Hemming Karlsen	
Manuscript ti	itle: Er leversygdomme et overset problem i Europa?	
Manuscript	number (if known): VPLED 205107	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments  (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	nning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
			Click TAB in last row to add extra ro

Tim	e frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None		
3	Royalties or licenses	⊠ None		

4	Consulting fees	□ None
		Novartis, Engitix, Intercept
5	Payment or honoraria for	□ None
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Gliead, AlfaSigma
6	Payment for expert testimony	⊠ None
7	Support for attending	⊠ None
	meetings and/or travel	
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None
11	Stock or stock options	□ None
		Ultimovacs
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	⊠ None
	services	
13	Other financial or non- financial interests	⊠ None
	Anna Maria	

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

## ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

form nomes. Alsland		
Your name: Aleksa	ander Krag	
Manuscript title:	Redaktør	
Manuscript number	if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		

Click TAB in last row to add extra rows

2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None	
		EU Horizon 2020	Coordinator of Galaxy, EU funded under grant agreement No 668031
		EU Horizon 2020	PI in LiverScreen, EU funded under grant agreemen No 847989
		EU Horizon 2020	PI in MicrobPredict, EU funded under grant agreement No 825694.
		EU Horizon 2020	PI in IHMCSA, EU funded under grant agreement No 964590

		Novo Nordisk Foundation	PI in MicrobLiver, A Challenge Grant, grant number NNF15OC0016692 from the Novo Nordisk Foundation	
		Innovationsfonden	Research funding, Innoexplorer	
		Danmarks Grundforskningsfond	PI in ATLAS, Grundforskningscenter	
		Region Syddanmark	Center grant for Elite Research Centre FLASH	
3	Royalties or licenses	<b>⊠</b> None		
147				
10-0	salther to mile and the	Read First As	SECTION AND PARTY OF THE PROPERTY SECTION	
	Complete			
4	Consulting fees	☑ None		
5	Payment or honoraria for	□ None		
	lectures, presentations,	Norgine	Lectures	
11 34	speakers bureaus,	Siemens	lectures, speaker's bureau	
	manuscript writing or	Siemens	lectures, speaker 3 bureau	
	educational events			
6	Payment for expert	☑ None		
	testimony			
7	Command for addition	67 11	WEST TO THE REST OF THE STATE O	
7	Support for attending meetings and/or travel	⊠ None		
	meetings and/or traver			
8 Patents planned, issued or		⊠ None		
	pending			
9	Participation on a Data	⊠ None		
	Safety Monitoring Board			
	or Advisory Board			
10	Leadership or fiduciary	<b>⊠</b> None		
	role in other board,	23 None		
	society, committee or			
	advocacy group, paid or			
	unpaid			
11	Stock or stock options	<b>☑</b> None		
12	Descipt of ogvinnent	□ N		
12	Receipt of equipment, materials, drugs, medical	None	Difference of the contract of	
	writing, gifts or other	Norgine	Rifaximin for an investigator initiated study, Galaxy	
	services	Ciamana	EU funded under grant agreement No 847989	
		Siemens	ELF test for an investigator initiated study	

	Echosence	Fibroscan for an investigator initiated study, LiverScreen EU funded under grant agreement No 847989
 Other financial or non-	☑ None	
financial interests		

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.